Please ensure Javascript is enabled for purposes of website accessibility

Why Anavex Life Sciences Blasted Higher Today

By Eric Volkman - Jun 21, 2021 at 4:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The good news keeps coming for one of the biotech's pipeline drugs.

What happened

Anavex Life Sciences (AVXL -4.34%) stock rocketed as much as 25% higher Monday before landing at a nearly 14% gain at market close. This was hardly surprising, as earlier in the day the company released some excellent news about one of its drug candidates.

So what

Anavex said in a press release that its ANAVEX 2-73, which targets several debilitating central nervous system (CNS) disorders, showed very promising results in a clinical trial. Specifically, the drug seems to activate a key receptor, Sigmar1.

The study was a phase 2 trial for the treatment of adult Rett syndrome patients. This is a rare CNS affliction that generally affects young girls; so far, it has no cure.

Medical professionals conferring in a hospital lobby.

Image source: Getty Images.

According to Anavex, data suggests that Sigmar1 activation "results in the restoration of complete housekeeping function within the body and is pivotal to restoring neural cell homeostasis and promoting neuroplasticity."

Participants in the trial demonstrated a "clinically meaningful and statistically significant ... improvement over placebo in the [Rett Syndrome Behavioral Questionnaire] total score, the trial's key efficacy endpoint." The biotech added that those patients saw balanced improvements during the seven-week study in such problem areas as body rocking, general mood, and repetitive hand behavior.

Now what

The new findings reinforce an encouraging article published in the Expert Opinion on Therapeutic Targets medical journal earlier this month on ANAVEX 2-73 and a related pipeline drug, ANAVEX 3-71, and their ability to activate Sigmar1. With the latest clinical data, the prospects for both treatments look even better.


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Anavex Life Sciences Corp. Stock Quote
Anavex Life Sciences Corp.
$10.58 (-4.34%) $0.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.